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Abstract: The dystrophin-glycoprotein complex (DGC) is a large trans-sarcolemmal complex 
that provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix. 
In skeletal muscle, it consists of the dystroglycan, sarcoglycan and cytoplasmic complexes, 
with dystrophin forming the core protein. The DGC has been described as being absent or 
greatly reduced in dystrophin-deficient muscles, and its lack is considered to be involved in 
the dystrophic phenotype. Such a decrease in the DGC content was observed in dystrophin-
deficient muscle from humans with muscular dystrophy and in mdx mice (X-linked Muscular 
Dystrophy). These deficits were observed in total muscle homogenates and in partially 
membrane-purified muscle fractions, the so-called KCl-washed microsomes. Here, we report 
that most of the proteins of the DGC are actually present at normal levels in the mdx mouse 
muscle plasma membrane. The proteins are detected in dystrophic animal muscles when the 
immunoblot assay is performed with crude surface membrane fractions instead of the usually 
employed KCl-washed microsomes. We propose that these proteins form SDS-insoluble 
membrane complexes when dystrophin is absent. 
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INTRODUCTION 
 
Duchenne Muscular Dystrophy (DMD) is a severe X-linked recessive and progressive 
muscle-wasting disease caused by genetic defects in the dystrophin gene leading to an 
absence of the protein. Dystrophin is a 427-kDa cytoskeletal protein located on the inner 
surface of the muscle fibres [1]. In skeletal and cardiac muscle, dystrophin is associated with 
a large complex of sarcolemmal and cytoskeletal proteins [2-4] which spans the sarcolemma. 
Together, dystrophin and the dystrophin-glycoprotein complex (DGC) provide a linkage 
between the extracellular matrix and the actin-based cytoskeleton.  
The DGC consists of three separate sub-complexes based on their locations within the cell 
and their physical associations with each other. These are the dystroglycan, 
sarcoglycan/sarcospan and cytoplasmic sub-complexes [5]. 
The dystroglycan sub-complex is composed of - and -dystroglycan, which are ubiquitously 
expressed in various tissues. Both are transcribed into a single protein that is subsequently 
cleaved into two associated proteins [6, 7]. -dystroglycan is an extracellular protein that 
binds to extracellular proteins such as laminin and agrin as well as to -dystroglycan [8]. -
dystroglycan is a transmembrane protein which binds to -dystroglycan outside the cell, and 
which interacts inside the cell with several proteins such as dystrophin, dystrophin-related 
proteins, caveolin-3 and Grb2 [9-12]. In addition, -dystroglycan binds to transmembrane 
sarcoglycans [13]. 
The sarcoglycan/sarcospan sub-complex consists of six transmembrane proteins, namely the 
-, -, -, -, -sarcoglycans and sarcospan. The sarcoglycans are all N-glycosylated 
transmembrane proteins with a short intracellular domain, a single transmembrane region and 
a large extracellular domain. Sarcospan is a protein with four transmembrane regions, and it 
belongs to the tetraspan family [14]. The sarcoglycan/sarcospan sub-complex interacts with 
the N-terminal region of -dystrobrevin [15].  
The cytoplasmic DGC complex contains syntrophins and dystrobrevins. The syntrophins are 
modular adaptor proteins. Among the -, 1-, 2- and 2- isoforms [16, 17], -syntrophin is 
the adult mouse skeletal muscle major isoform. The syntrophins interact with dystrophin, 
utrophin or dystrobrevins [16], and with several other proteins like ErbB4, Na-Channels and 
nNOS [18]. The dystrobrevins are encoded by two  and  separate genes and are involved in 
the signalling function of the DGC [19, 20].  
The DGC is thought to contribute to the structural stability of the muscle cell membrane 
during cycles of contraction and relaxation, thereby protecting the muscle from stress-induced 
membrane damage [21, 22]. In DMD patients and animals displaying muscular dystrophy 
associated with dystrophin deficiency, such as mdx (X-linked Muscular Dystrophy) mice, it is 
currently considered that the absence of dystrophin leads to a drastic reduction of all the 
dystrophin-associated proteins in the sarcolemma, thus causing a disruption of the linkage 
between the subsarcolemmal cytoskeleton and the extracellular matrix [3, 23-25]. This is 
presumed to cause sarcolemmal instability, which, in turn, may render muscle fibres 
susceptible to necrosis. That is why the efficacy of dystrophin gene therapy depends not only 
on replacing dystrophin but also on restoring all of the DGC in the sarcolemma of DMD 
patients. 
However, it is not possible to distinguish any difference in the expression levels of 
dystroglycan and sarcoglycan mRNA between normal and mdx mice [6, 26, 27]. Moreover, in 
a previous study, we showed that -dystroglycan is targeted onto the plasma membrane in 
similar amounts in both normal and mdx mouse muscle: it was detected in crude surface 
membranes instead of microsomes by routine methods [28].  
In this study, we investigate the status of DGC in the skeletal muscle of mdx mice to ascertain 
whether or not the dystrophin-associated proteins are present in the crude surface membranes 
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(CSM) as shown for -dystroglycan [28]. Here, we demonstrate that all of the studied 
dystrophin-associated proteins are actually present and detectable at high levels in the crude 
surface membranes from mdx skeletal muscle, complementing our previous finding that -
dystroglycan can be detected in mdx mouse muscle. This result suggests that the DGC is 
synthesized at a normal level and targeted onto the plasma membrane in dystrophin-deficient 
mouse muscle. However, the organisation of the DGC renders them SDS-invisible in KCl-
washed microsomes and SDS-visible in crude surface membranes. 
 
MATERIALS AND METHODS 
 
Animals 
Male normal (C57BL/10Sc/Scn) and mdx (C57BL/10Sc/Scn/mdx) mice were bred at the 
Ecole Nationale Vétérinaire in Nantes. They were given free access to water and standard 
laboratory chow. All the experiments complied with the French legislation and guidelines for 
animal experimentation. We have the official authorizations for work on laboratory animals 
from the French Agriculture Ministry. Thirty animals per series, mdx or normal, were used for 
these experiments. 
 
Antibodies 
Mouse anti-Na/K-ATPase was obtained from USABiomax (Euromedex, Mundolsheim, 
France). Mouse anti--dystroglycan (NCL-b-DG), anti--sarcoglycan (NCL-b-SARC), anti--
sarcoglycan (NCL-g-SARC) and anti-dystrophin (NCL-DYS1 and NCL-DYS2) were 
supplied by Novocastra Laboratories (Tebu-Bio SA, Le Perray en Yvelines, France). Mouse 
anti--dystrobrevin was purchased from BD Biosciences Laboratories (Le Pont de Claix, 
France), mouse anti--syntrophin (ab11425) from Abcam (Paris, France), and mouse anti-
calsequestrin (VIIID12) from Affinity BioReagents (Ozyme, Saint Quentin Yvelines, France). 
Rabbit anti--sarcoglycan (R607) and anti--sarcoglycan (-Sarc/12C1) were provided by 
S.J. Winder (Department of Biomedical Science, Sheffield, UK). Rabbit anti--sarcoglycan 
was a gift from J.R. Sanes (Harvard University, Molecular and Cellular Biology, Cambridge, 
MA, USA). Alkaline phosphatase conjugated anti-mouse and anti-rabbit secondary antibodies 
were from Sigma-Aldrich (Lyon, France). 
 
Isolation of crude surface membranes 
Normal and mdx mice (16-20 weeks old) were euthanized by intraperitoneal pentobarbital 
injection, and whole hind-leg muscle samples were taken. KCl-washed microsomes (KCl-Ms) 
and CSM were isolated by velocity sedimentation at 4ºC as described previously [28, 29]. 
Briefly (see Fig. 1), the muscle was homogenized in buffer A (20 mM sodium pyrophosphate, 
20 mM sodium phosphate, 1 mM MgCl2, 0.303 M sucrose, 0.5 mM Ethylene-diamine-tetra-
acetic acid (EDTA), at pH 7.0, with protease inhibitors). The homogenate was centrifuged for 
25 min at 14000 g. The pellet was resuspended in buffer A and centrifuged as described in the 
previous step. The supernatants were combined and subjected to centrifugation for 40 min at 
17000 g. The supernatant was incubated with KCl for 30 min at 4ºC to obtain a final 
concentration of 0.6 M KCl for the suspension. After centrifugation for 35 min at 140000 g, 
the pellet was resuspended in buffer B (0.303 M sucrose, 20 mM Tris-maleate, at pH 7.0, with 
protease inhibitors) and centrifuged again for 35 min at 140000 g to obtain the KCl-M 
fraction. The KCl-Ms were resuspended in buffer B containing 0.6 M KCl, loaded onto 0.878 
M sucrose, 0.6 M KCl, 20 mM Tris-Maleate, at pH 7, and centrifuged at 104000 g for 17 h. 
CSM were collected above the 0.303 M / 0.878 M sucrose interface, and three other fractions 
were obtained above the interface of the two sucrose concentrations (F2), below the interface 
(F3) and at the bottom as the pellet fraction (F4). The CSM (F1) was further concentrated as a 
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pellet by a final centrifugation for 4 h at 104000 g, and the supernatant was recovered (F5). 
The proteins
 
were quantified with a colorimetric assay (Bradford
 
Reagent, Bio-Rad, Marne La 
Coquette, France). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Skeletal muscle fractionation: the purification protocol. 
Buffer A is composed of 20 mM sodium pyrophosphate, 20 mM sodium phosphate, 1 mM 
MgCl2, 0.303 M sucrose and 0.5 mM EDTA, at pH 7.0, with protease inhibitors. Buffer B is 
composed of 0.303 M sucrose and 20 mM Tris-maleate, at pH 7.0. 
 
To quantify the total recovery of the gradient, volumes containing 200 g of protein from 
each fraction (F1 to F5) were precipitated with 10% trichloroacetic acid. After 30 min 
incubation at 4ºC, the samples were centrifuged at 20000 g for 15 min at 4ºC. The protein 
pellets were washed twice with cold acetone and centrifuged under the same conditions as 
described above. The final pellets were dried and subjected to SDS-PAGE analysis. 
 
SDS-PAGE and immunoblotting 
SDS-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) was performed on polyacrylamide 
gels according to Laemmli [30], with proteins being transferred to nitrocellulose [31]. In brief, 
40 µg aliquots of protein were boiled in 2%-SDS buffer with 5% -mercaptoethanol, 
separated by SDS-PAGE, and electrophoretically transferred from gel to nitrocellulose filters 
at 4ºC. The efficiency of transfer was evaluated by Ponceau-S-Red staining of membranes, 
following by destaining in Tris-Buffered Saline (TBS: 20 mM Tris-HCl, 500 mM NaCl, pH 
7.5) / 0.01% Tween. The filters were blocked with 5% nonfat dry milk / 0.01% Tween 20 in 
TBS, and then incubated overnight with primary antibody appropriately diluted in blocking 
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buffer. The blots were subsequently washed twice for 15 min in blocking solution and then 
incubated for 1 h with appropriate alkaline phosphatase-conjugated secondary antibodies. 
After being washed 3 times for 10 min with TBS, the immunoblots were developed using a 
chemifluorescent substrate for alkaline phosphatase (ECF, Amersham Biosciences, Orsay, 
France), and the chemifluorescence emission was directly measured by fluorescence scanning 
(Storm Instrument, Amersham, and Image-Quant 5.2). The values are expressed as arbitrary 
units (AU) corresponding to the protein-specific signal corrected for the background (the 
value used for the background is the average of all the pixel values in the object outline). The 
linearity between the chemifluorescence levels and protein contents was first tested. The 
potential level variations were compared in the same gel with the arbitrary unit reference 
value of 100 for the KCl-M chemifluorescence.  
 
Statistical analysis 
For each protein studied, we performed three independent muscle fractionations for each 
genotype and three corresponding western blot analyses, with each membrane carrying all the 
compared fractions. The data is expressed as the mean ± SEM. We used the Mann-Whitney U 
test to evaluate differences in the labelling levels between the fractions. A p value of less than 
0.05 was considered statistically significant. 
 
RESULTS 
 
Muscle fractionation 
Before characterizing the DGC, we extensively checked the method of plasma membrane 
purification, as derived from the work of Ohlendieck and Campbell [2], as regards the yield 
and composition of marker proteins in the fractions previously described [28]. To confirm 
successful fractionation, equal amounts of KCl-Ms and CSM, from normal and dystrophin-
deficient animals, were analysed by immunoblot assay using antibodies against calsequestrin, 
a marker of the sarcoplasmic reticulum, and Na/K-ATPase, an established plasma-membrane 
marker (Fig. 2). In the two animal lines, calsequestrin labelling was strong in the KCl-Ms and 
markedly reduced in the CSM. By contrast, the CSM was enriched in Na/K-ATPase 
compared to the KCl-Ms. These results show that the KCl-Ms comprise sarcoplasmic 
reticulum and plasma membranes, while the CSM fraction appears to be mainly devoid of 
sarcoplasmic membranes and largely enriched in plasma membranes. On the other hand, 
comparable levels of calsequestrin expression are found in normal and mdx muscle, both in 
the KCl-Ms and in CSM fractions (Fig. 2). This indicates that the membrane preparations are 
similarly affected whether they come from dystrophin-deficient or normal muscle. As 
illustrated in Fig. 2, the dystrophin isoform Dp427 (detected with two antibodies, NCL-DYS1 
and NCL-DYS2, which respectively recognize the dystrophin rod domain and C-terminal 
region) is not present in KCl-Ms and CSM isolated from mdx muscle homogenates, as 
expected. 
These data show that the fractionation method does not disturb the marker protein 
composition of dystrophic compared to normal fractions, thus verifying the high degree of 
purity of the sarcolemmal preparations used in this study. Moreover, equal amounts of 
sarcolemmal proteins are present in the different membrane preparations, as shown by 
Ponceau red staining (Fig. 2). 
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Fig. 2. Detection of subcellular fractionation procedure markers. 
Nitrocellulose transfers of SDS-PAGE are shown, containing 40 µg of KCl-washed 
Microsomes (1, 3) or Crude Surface Membranes (2, 4) from normal or dystrophic (mdx) mice, 
stained with the antibodies against calsequestrin, Na/K-ATPase and dystrophin (DYS1 and 
DYS2 antibodies respectively recognizing the rod domain and C-Terminal region). The 
Ponceau red staining of membranes, shown at the bottom, reveals a comparable overall 
protein composition of the normal and dystrophic fractions for KCl-Ms and CSM. 
 
Gradient recovery 
Five fractions (F1 to F5) were recovered after loading KCl-Ms onto a sucrose density 
gradient, and their volumes and protein contents were measured. 200 µg of proteins from each 
of the five fractions were precipitated using trichloroacetic acid, and SDS-PAGE was carried 
out followed by western blotting with -dystroglycan antibody to quantify the contents of the 
five fractions (Tab. 1 and Tab. 2). 
 
Tab. 1. Gradient recovery data. 
Total volumes and protein contents of the KCl-Ms and of the five fractions obtained after 
applying a sucrose density gradient to KCl-Ms from normal and mdx mouse muscle.  
 
 Normal mouse muscle Mdx mouse muscle 
Fractions Volume (mL) Protein (mg) Volume (mL) Protein (mg) 
KCl-Ms 1 26 1 29 
F1, CSM  0.21 2.00 ± 0.02 0.35 4.00 ± 0.30 
F2  0.50 1.25 ± 0.25 0.50 1.10 ± 0.10 
F3 30.00 4.50 ± 0.35 29.00 7.50 ± 0.35 
F4 0.90 20.00 ± 0.50 0.75 17.00 ± 0.77 
F5  20.00 - 20.00 - 
Total F1 to F5   27 mg   29 mg 
 
Na/K-ATPase 
Ponceau red  
Dystrophin, DYS1 
Dystrophin, DYS2 
Calsequestrin 
Normal             mdx 
1          2          3          4 
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About 30 mg of protein in 1 mL were loaded onto the sucrose density gradient, using 
preparations from normal and mdx mouse muscle. The whole amount of protein loaded was 
recovered in the five fractions of the gradient (Tab. 1). The pellet F4 contained 58-75 % of the 
total protein content in the two muscle preparations. Surprisingly, the protein content of the 
CSM (fraction F1) was twice as high in mdx mouse muscle as in normal muscle. 
Firstly, from Fig. 3 and Tab. 2, it is evident from the sum of the contents of the five fractions 
that there was a total recovery of the total -dystroglycan content of the normal muscle KCl-
Ms loaded onto the sucrose density gradient. By contrast, the total -dystroglycan content 
obtained by summing the five fraction contents from mdx mouse muscle was three times 
higher than the content of the corresponding KCl-M protein loaded on the gradient. This 
clearly indicates that 2/3 of the -dystroglycan content of the KCl-Ms from mdx mouse 
muscle is not detected by classic SDS-PAGE and western-blot, in contrast to normal muscle 
KCl-Ms. This also implies that during application of the sucrose density gradient, a high 
amount of β-dystroglycan from the mdx mouse muscle becomes accessible to SDS in an as-
yet unexplained process. This validates and further supports our previous results.  
 
Fig. 3. Immunoblotting of β-dystroglycan in the KCl-Ms and the five fractions from the 
sucrose density gradient of these KCl-Ms from normal and mdx mouse muscle. 
40 µg of TCA-precipitated proteins from each fraction were loaded on an SDS-PAGE and 
blotted. β-dystroglycan immunoblots were developed using a chemifluorescent substrate for 
alkaline phosphatase, and the chemifluorescence emission was directly measured on the blots. 
The values are shown in Tab. 2.  
 
Secondly, it appears that the two -dystroglycan species (43 and 30 kDa) show different 
distributions in the mdx and normal mouse muscle gradient fractions. The 30-kDa band 
accounted for about 10% of the total content in normal mouse muscle, while this percentage 
rose to about 43% in the mdx mouse muscle total fractions. The two -dystroglycan species 
yielded dissimilar distributions in the different fractions obtained after the gradient: a higher 
percentage of the 30-kDa -dystroglycan band was recovered in the CSM (F1) in normal 
(23%) and mdx (56%) mouse muscle fractions compared to the 43-kDa β-dystroglycan band, 
while lower percentages were observed in the gradient pellet (F4), which was mainly 
composed of sarcoplasmic reticulum membranes (3.7 and 20% of -dystroglycan 30-kDa 
compared to the -dystroglycan 43-kDa in F4 from normal and mdx mouse muscle, 
respectively). This suggests that the -dystroglycan 30-kDa band is preferentially present in 
the lightest fractions of the sucrose density gradient. Interestingly, the -dystroglycan 30-kDa 
band from normal mouse muscle behaves as if it was obtained from a mdx muscle in the sense 
that the amount detected in the KCl-M fraction (22 AU) is lower than the total amount 
detected in F1 to F5 (44 AU).  
However, the fact that β-DG was recovered in great amounts in F3 and F4 does not mean that 
the protein could be associated with other cellular structures than the sarcolemma. As shown 
earlier, during the procedure used to obtain sarcolemmal fractions, vesicles can be trapped in 
each other, i.e. sarcoplasmic reticulum vesicles can trap sarcolemma vesicles and vice versa. 
Therefore, the isolation procedure essentially removes excess sarcoplasmic reticulum vesicles 
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from the CSM [29], and the F4 fraction contains an excess of sarcoplasmic reticulum vesicles 
compared to the CSM. We previously showed that the F4 fraction from mdx mouse muscle 
already contains utrophin. In addition, there is a difference in the distribution of β-
dystroglycan when comparing the fractions F3 and F4 from normal and mdx mouse muscles. 
However, a sucrose density gradient separates the different membrane vesicles in function of 
their protein/lipid ratio and their sizes. It is likely that the dystrophin deficiency could modify 
the sedimentation coefficient of the membranes from mdx mice, and this would account for 
the modified distribution and for the fact that the CSM were in all cases recovered in higher 
amounts in the mdx compared to the normal KCl-Ms. 
 
Tab. 2. -dystroglycan recovery over the gradient. 
The five fractions obtained after the gradient were precipitated with trichloroacetic acid, and 
then SDS-PAGE and western-blot analysis were performed for -dystroglycan. The -
dystroglycan level quantified by chemifluorescence is reported for the total volume of the 
different fractions. 
 
 Total chemifluorescence (arbitrary units) calculated from the -DG bands 
observed on western blots* 
Fractions Normal mouse muscle mdx mouse muscle 
 Total  
-DG 
43 kDa 
-DG 
30 kDa 
-DG 
Total  
-DG 
43 kDa 
-DG 
30 kDa 
-DG 
KCl-Ms 465 443 22 165 105 60 
F1, CSM  65 50 15 170 75 95 
F2  20 16 4 20 10 10 
F3 110 95 15 200 115 85 
F4 270 260 10 90 72 18 
F5  -   -   
Total F1  
to F5 
465 421 44 480 272 208 
*the calculations are as follows: (fluorescence of the western blot bands / protein content of 
the loaded sample) x total protein content of the fraction. 
 
DGC proteins in KCL-Ms and CSM from normal and mdx mouse muscle 
To quantify the dystrophin-associated protein levels in dystrophin-deficient versus normal 
skeletal muscle membranes, we performed chemifluorescence analyses of immunoblots from 
KCl-M and CSM fractions from normal and mdx mice. 
In the normal mouse muscle KCl-Ms, immunoblot labelling with antibodies against DGC 
proteins demonstrated the presence of -dystroglycan, the -, -, -, - and -
sarcoglycansFig. 4Aand-dystrobrevin and -syntrophin (Fig. 4B) at their respective 
expected sizes. For -sarcoglycan (Fig. 4A), a close doublet of bands was detected at 
approximately 35 kDa, corresponding to alternatively spliced products. Dystrobrevin labelling 
(Fig. 4B) revealed 3 major bands (87, 59 and 35 kDa) corresponding to the three major mouse 
-dystrobrevin isoforms (types 1, 2 and 3). For the other proteins, we found a unique band at 
the expected size.  
The labelling of these DGC proteins was strongly and significantly enhanced in the CSM 
compared to KCl-Ms (Fig. 4A-B), as shown in the histograms reporting the 
chemifluorescence quantitative values of the western-blots for each protein. For -
dystroglycan, a second band that is absent from the KCl-Ms appeared at 30 kDa in the CSM. 
These results confirm that the muscle fractionation process induces a concentration of 
sarcolemmal proteins in the CSM fraction. 
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In the KCl-Ms of mdx mouse muscle, the DGC proteins appeared greatly reduced compared 
to the KCl-Ms in normal mouse muscle (Fig. 4A-B), as previously reported in numerous 
studies. However, in mdx mouse muscle CSM, most of the DGC proteins exhibited similar or 
higher contents compared with the values observed in normal mouse muscle CSM (Fig. 4A-
B). Fig. 4A and Fig. 4B show a representative assay of this protein label across three similar 
assays. In particular, the -dystroglycan 43-kDa band was detected at similar levels in normal 
and mdx CSM, while the 30-kDa band was highly enriched specifically in CSM extracted 
from mdx mice (Fig. 4A). Therefore, the total content of -dystroglycan was higher in mdx 
than in normal mouse muscle CSM. The -, -, -, - and -sarcoglycans were all at a similar 
level in mdx compared to normal mouse muscle CSM. The 87-kDa -dystrobrevin-1 isoform 
was slightly depleted in mdx compared to normal mouse muscle CSM, while the 59- and 35-
kDa -dystrobrevin-2 and -3 isoforms were severely depleted in CSM from mdx mice 
compared to normal mice (Fig. 4B). 
In summary, our results show that the KCl-Ms of mdx mouse muscle exhibit a dramatic 
decrease in DGC proteins compared to normal mouse muscle, as previously reported in 
numerous studies. However, we show that, in contrast to the KCl-Ms, such a dramatic 
depletion of the DGC proteins is not observed in the CSM from mdx mouse muscle compared 
to normal mouse muscle, but rather that these proteins display very similar levels in both 
types of CSM fraction. The increase in the level of DGC protein in CSM as against KCl-Ms 
in normal mouse muscle occurs during sarcolemmal purification via the fractionation 
procedure. However, this purification cannot explain the large variation in protein levels that 
was observed, ranging from very low contents in KCl-Ms to high contents in CSM from mdx 
mouse muscle. 
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Fig. 4. Immunoblotting of DGC proteins in KCl-Ms and CSM from normal and mdx mouse 
muscle. 
Immunoblots of -dystroglycan and sarcoglyan complex proteins (A) and cytoplasmic 
complex (B) are presented. Representative nitrocellulose transfers of SDS-PAGE are shown, 
containing 40 µg of KCl-Ms or CSM from normal or dystrophic (mdx) mice, stained with 
antibodies against -dystroglycan,-, -, -, - and -sarcoglycan (A), and -dystrobrevin 
and -syntrophin (B). The protein amounts are presented as histograms showing the 
chemifluorescence measured on the blots. The results are expressed as arbitrary units, with a 
reference value being assigned to KCl-washed Microsomes (KCl-Ms) from normal mice. 
Each value is the mean ± SEM from three independent series of subcellular fractionation and 
immunoblot assays from three identical batches of mice. *significant difference between KCl-
Ms and CSM in the same group and **significant difference between the groups for the same 
fraction, (p < 0.05) according to the Mann-Whitney U test procedure. 
A 
B 
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DISCUSSION 
 
Our previous study showed that -dystroglycan is actually present at high levels in the 
skeletal muscle plasma membrane of mdx mice [28], although this was not detected by the 
classical immunoblot analysis of the microsomes. The aim of this study was to discover 
whether this is the general rule for all the DGC proteins. For this purpose, we carried out sub-
cellular fractionation of normal and dystrophin-deficient muscles to obtain so-called KCl-
washed microsomes (KCl-Ms) and crude surface membranes (CSM) after a final sucrose 
density gradient centrifugation of the KCl-Ms. Both normal and dystrophin-deficient mdx 
mouse muscles were subjected to this fractionation procedure.  
Many studies report a dramatic decrease in the levels of DGC proteins in dystrophin-deficient 
muscle homogenates and KCl-Ms [3, 23-25], and the re-appearance of the DGC proteins has 
been used as a significant indicator for quantifying phenotype rescue after therapy strategies 
performed on dystrophin-deficient animals [32-40]. As in all those studies, we showed that -
dystroglycan, taken as a marker of the DGC proteins, is greatly depleted in KCl-Ms from mdx 
mouse compared to normal mouse muscle.  
However, we know that the KCl-Ms represent a very heterogeneous mixing of intracellular 
and sarcolemma membranes, and our current results concur with this point. Therefore, we 
report here on an attempt to quantify precisely the depletion of the DGC proteins in 
dystrophin-deficient muscle, based on an estimation of the contents of these proteins in a 
muscle fraction highly purified in sarcolemma membranes. In this study, we subjected the 
KCl-Ms to a sucrose density gradient centrifugation to obtain a crude sarcolemma membrane 
fraction (CSM) highly enriched in specific sarcolemma proteins such as dystrophin, -
dystroglycan and Na
+
/K
+
-ATPase. In our previous study [28], we showed that the CSM 
fraction was not dramatically depleted in -dystroglycan when obtained from mdx mouse 
muscle. However, we also found that this protein was present at a level similar to that seen in 
CSM from normal mouse muscle. Here, we showed that: i) the gradient recovery of KCl-Ms 
in mdx mouse muscle indicates that the sum of the -dystroglycan levels in the different 
fractions of the gradient is three times higher than the level of KCl-M -dystroglycan loaded 
onto the gradient; and ii) this increase in the -dystroglycan level in mdx mouse muscle CSM 
is the general rule for all members of the DGC. 
The gradient recovery is obtained by studying the -dystroglycan levels in the different 
fractions obtained after sucrose density gradient centrifugation of the KCl-Ms. In the case of 
normal muscle, the sum of the -dystroglycan levels in the fractions after the gradient is equal 
to the -dystroglycan content in the KCl-Ms that were loaded onto the gradient, as expected 
from such an experiment. However, in the case of mdx mouse muscle, the sum of the -
dystroglycan levels in the fractions after the gradient is three times higher than the content of 
the KCl-Ms loaded onto the gradient, which is a very unusual finding. This result implies that, 
in accordance with our previous observations, a large proportion of the -dystroglycan (2/3) 
is not visible in the KCl-Ms. After the gradient, it would appear that this large amount 
becomes visible owing to an as-yet unknown mechanism.  
We show that six out of the seven other DGC proteins studied here are actually present in the 
CSM of mdx mouse muscle at levels similar to those observed in the CSM from normal 
mouse muscle. In a similar way to -dystroglycan, we conclude that these DGC proteins are 
invisible in the KCl-Ms but become visible in the fractions recovered after the gradient. 
As these proteins are observed at their expected sizes, the difference in detection between 
KCl-Ms and CSM cannot be due to altered post-translational modifications as previously 
shown for -dystroglycan, for which some authors report a lack of detection by the VIA4-1 
antibody [41]. In mdx muscle, most of the DGC proteins display normal mRNA levels [6, 26, 
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42]. Since these proteins are detected in CSM purified from the KCl-Ms fraction, they appear 
to be synthesized in normal amounts and not degraded in the absence of dystrophin. As an 
exception, β-DG appears as two bands with the light band at 30 kDa becoming prominent in 
mdx compared to normal muscle preparations. Such a cleavage product was already observed 
in cancer cells [43] and in ischemic heart tissue [44] being due to the release of the β-DG 
extracellular domain by metalloproteinases. It seems likely that such a cleavage is activated 
during the purification procedure. This hypothesis was reinforced by the observation of a 
specific increase of this band in the CSM compared to KCl-Ms obtained from normal muscle. 
In biochemical studies, the proteins were rendered soluble by the charge buffer [30] before the 
SDS-PAGE by means of 2% SDS and 5% -mercaptoethanol and boiling at 95ºC. Our results 
indicate that a large part of the β-dystroglycan and DGC proteins in KCl-Ms are not visible 
with this charge buffer, which is likely due to non-solubility in SDS. This type of behaviour is 
already known for membrane proteins where specific strategies are used in proteomic 
approaches to solubilize these proteins [45, 46]. SDS-insoluble proteins are known to 
accumulate in several disorders: for example, dysferlin in Alzheimer’s disease [47], 
polyglutamates in PolyQ neurodegenerative diseases [48], and -synuclein in Parkinson’s 
disease [49]. In our study, DGC proteins appear to form oligomers or SDS-insoluble 
aggregates that accumulate in the sarcolemma. These insoluble aggregates are made up of 
sarcoglycans, -dystroglycan, -syntrophin and -dystrobrevin-1. Since these aggregates are 
modified by the density gradient centrifugation step, the proteins become accessible to SDS 
and antibodies for immunoblotting. At present, we have no explanation for this surprising 
observation. It appears also clear that if the DGC proteins are not soluble in the SDS-PAGE 
sample buffer as they are not accessible to the antibodies on the western-blot, they would also 
be inaccessible to the antibodies in immunocytochemical experiments in which there is no 
attempt to solubilize the proteins by any treatment.  
Our results imply that, in the plasma membrane of mdx mouse muscle, the cytoplasmic 
proteins -dystrobrevin-1 and -syntrophin make up an insoluble sub-complex that is 
associated with the intrinsic membrane proteins, sarcoglycans and dystroglycans. Because -
dystrobrevin-2 is highly depleted, we may conclude that this cytoplasmic isoform is only 
linked to dystrophin in normal muscle; -dystrobrevin-3 is not detected in mdx mouse muscle, 
even though it links to sarcoglycans, which are still present. However, since sarcoglycans are 
not accessible to the cytoplasmic side, being embedded in a large membrane complex, this 
would make them inaccessible to -dystrobrevin-3, which, in turn, is either not present in the 
cell or not retained in the plasma membrane fractions. -dystrobrevin-1 co-purifies with 
utrophin and is still retained in CSM. 
All these findings suggest that while the DGC proteins are produced at normal levels in mdx 
mice, they may not be properly assembled and/or integrated into the sarcolemma. It appears 
that they form inaccessible membrane complexes when dystrophin is deficient. This could be 
reversed by the expression of the dystrophin-related protein Dp71 in mdx skeletal muscle [32, 
50], even though the expression of Dp71 results in severe muscle degeneration. Moreover, 
several of the DGC proteins are partly visible in KCl-Ms in mdx mouse muscle depending on 
the protocol used. In particular, -dystroglycan could be detected in mdx mouse muscle at 
about 50% of the level in normal muscle. This partial visibility is likely due to interactions 
with other partners apart from dystrophin, such as utrophin or plectin. Utrophin is over-
expressed in DMD and mdx mouse muscle, and is able to bind to -dystroglycan [25, 36], 
while plectin is a newly revealed partner of -dystroglycan [51]. We propose that the direct 
interaction between these two proteins and -dystroglycan could explain the remaining partial 
visibility of the -dystroglycan in mdx mouse muscle. In line with the demonstration that the 
dystroglycan and sarcoglycan sub-complexes may be dystrophin-independent signaling or 
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regulatory modules [52, 53], our results also suggest that the expression of most of the DGC 
proteins is independent of dystrophin expression, while their functional localization depends 
partly on the correct localization of dystrophin and, in particular, on the presence of the β-
dystroglycan-binding domain. 
 
ACKNOWLEDGEMENTS 
 
We are grateful to S.J. Winder and J.R. Sanes for their gifts of antibodies. We would like to 
thank A. Bondon and J.-F. Hubert for their encouraging discussions and suggestions. This 
study was supported by the Association Française contre les Myopathies (AFM) and the 
COREC of the Université de Rennes I. The English style was corrected by a professional 
translator, Dr. M.S.N. Carpenter. 
 
REFERENCES 
 
1. Hoffman, E.P., Brown, R.H. and Kunkel, L.M. Dystrophin: the protein product of the 
Duchenne muscular dystrophy locus. Cell 51 (1987) 919-928. 
2. Ohlendieck, K., Ervasti, J.M., Snook, J.B. and Campbell, K.P. Dystrophin-
glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. J. 
Cell Biol. 112 (1991) 135-148. 
3. Ervasti, J., Ohlendieck, K., Kahl, S., Gaver, M. and Campbell, K. Deficiency of a 
glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345 
(1990) 315-319. 
4. Campbell, K. and Kahl, S. Association of dystrophin and an integral membrane 
glycoprotein. Nature 338 (1989) 259-262. 
5. Ervasti, J.M. and Sonnemann, K. Biology of the striated muscle dystrophin-
glycoprotein complex. Int. Rev. Cytol. 265 (2008) 191-225. 
6. Ibraghimov-Beskrovnaya, O., Ervasti, J., Leveille, C., Slaughter, C., Sernett, S. and 
Campbell, K. Primary structure of dystrophin-associated glycoproteins linking 
dystrophin to the extracellular matrix. Nature 355 (1992) 696-702. 
7. Smalheiser, N.R. and Kim, E. Purification of cranin, a laminin binding membrane 
protein. Identity with dystroglycan and reassessment of its carbohydrate moieties. J. 
Biol. Chem. 270 (1995) 15425-15433. 
8. Winder, S. The complexities of dystroglycan. Trends Biochem. Sci. 26 (2001) 118-
124. 
9. Chung, W. and Campanelli, J.T. WW and EF hand domains of dystrophin-family 
proteins mediate dystroglycan binding. Mol. Cell Biol. Res. Commun. 2 (1999) 162-
171. 
10. Huang, X., Poy, F., Zhang, R., Joachimiak, A., Sudol, M. and Eck, M.J. Structure of a 
WW domain containing fragment of dystrophin in complex with beta-dystroglycan. 
Nat. Struct. Biol. 7 (2000) 634-638. 
11. Yang, B., Jung, D., Motto, D., Meyer, J., Koretzky, G. and Campbell, K.P. SH3 
Domain-mediated Interaction of Dystroglycan and Grb2. J. Biol. Chem. 270 (1995) 
11711-11714. 
12. Hnia, K., Zouiten, D., Cantel, S., Chazalette, D., Hugon, G., Fehrentz, J.A., 
Masmoudi, A., Diment, A., Bramham, J., Mornet, D. and Winder, S.J. ZZ domain of 
dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. 
Biochem. J. 401 (2007) 667-677. 
  14 
13. Yoshida, T., Pan, Y., Hanada, H., Iwata, Y. and Shigekawa, M. Bidirectional signaling 
between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J. 
Biol. Chem. 273 (1998) 1583-1590. 
14. Crosbie, R.H., Lebakken, C.S., Holt, K.H., Venzke, D.P., Straub, V., Lee, J.C., Grady, 
R.M., Chamberlain, J.S., Sanes, J.R. and Campbell, K.P. Membrane targeting and 
stabilization of sarcospan is mediated by the sarcoglycan subcomplex. J. Cell Biol. 
145 (1999) 153-165. 
15. Yoshida, M., Hama, H., Ishikawa-Sakurai, M., Imamura, M., Mizuno, Y., Araishi, K., 
Wakabayashi-Takai, E., Noguchi, S., Sasaoka, T. and Ozawa, E. Biochemical 
evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a 
basis for understanding sarcoglycanopathy, Hum. Mol. Genet. 9 (2000) 1033-1040. 
16. Ahn, A.H., Freener, C.A., Gussoni, E., Yoshida, M., Ozawa, E. and Kunkel, L.M. The 
three human syntrophin genes are expressed in diverse tissues, have distinct 
chromosomal locations, and each bind to dystrophin and its relatives. J. Biol. Chem. 
271 (1996) 2724-2730. 
17. Peters, M.F., Adams, M.E. and Froehner, S.C. Differential association of syntrophin 
pairs with the dystrophin complex. J.Cell Biol. 138 (1997) 81-93. 
18. Ervasti, J.M. Dystrophin, its interactions with other proteins, and implications for 
muscular dystrophy. Biochim. Biophys. Acta 1772 (2007) 108-117. 
19. Peters, M., O'Brien, K., Sadoulet-puccio, H., Kunkel, L., Adam, M. and Froehner, S. 
-dystrobrevin,a new member of the dystrophin family. J. Biol. Chem. 272 (1997) 
31561-31569. 
20. Blake, D.J. Dystrobrevin dynamics in muscle-cell signalling: a possible target for 
therapeutic intervention in Duchenne muscular dystrophy? Neuromuscul. Disord. 12 
Suppl 1 (2002) S110-117. 
21. Campbell, K.P. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix 
linkage. Cell 80 (1995) 675-679. 
22. Petrof, B.J., Shrager, J.B., Stedmann, H.H., Kelly, A.M. and Sweeney, H.L. 
Dystrophin protects the sarcolemma from stresses developed during muscle 
contraction. Proc. Natl. Acad. Sci. USA 90 (1993) 3710-3714. 
23. Ohlendieck, K. and Campbell, K.P. Dystrophin-associated proteins are greatly reduced 
in skeletal muscle from mdx mice. J. Cell Biol. 115 (1991) 1685-1694. 
24. Ohlendieck, K., Matsumura, P., Ionasescu, V., Towbin, J., Bosch, E., Weinstein, S., 
Sernett, S. and Campbell, K.P. Duchenne muscular dystrophy: deficiency of 
dystrophin-associated proteins in the sarcolemma. Neurology 43 (1993) 795-800. 
25. Ozawa, E., Yoshida, M., Suzuki, A., Mizuno, Y., Hagiwara, Y. and Noguchi, S. 
Dystrophin-associated proteins in muscular dystrophy. Hum. Mol. Genet. 4 Spec No 
(1995) 1711-1716. 
26. Hack, A., Lam, M., Cordier, L., Shoturma, D.I., Ly, C.T., Hadhazy, M.A., Hadhazy, 
M.R., Sweeney, H.L. and McNally, E.M. Differential requirement for individual 
sarcoglycans and dystrophin in the assembly and function of the dystrophin-
glycoprotein complex. J. Cell Sci. 113 (2000) 2535-2544. [Record as supplied by 
publisher]. 
27. Rouger, K., Cunff, M.L., Steenman, M., Potier, M., Gibelin, N., Dechene, C. and 
Leger, J. Global/temporal gene expression in diaphragm and hindlimb muscles of 
dystrophin-deficient (mdx) mice. Am. J. Physiol. Cell Physiol. 253 (2002) C773-
C784. 
28. Cluchague, N., Moreau, C., Rocher, C., Pottier, S., Leray, G., Chérel, Y. and Le 
Rumeur, E. -dystroglycan can be revealed in microsomes from mdx mouse muscle 
by detergent treatment. FEBS Letters 572 (2004) 216-220. 
  15 
29. Ohlendieck, K. Characterisation of the dystrophin-related protein utrophin in highly 
purified skeletal muscle sarcolemma vesicles. Biochim. Biophys. Acta 1283 (1996) 
215-222. 
30. Laemmli, U. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227 (1970) 680-685. 
31. Towbin, H., Staehelin, T. and Gordon, J. Electrophoresis transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. 
Natl. Acad. Sci. USA 76 (1979) 4350-4354. 
32. Cox, G.A., Sunada, Y., Campbell, K.P. and Chamberlain, J.S. Dp71 can restore the 
dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy, 
Nature Genet. 8 (1994) 333-339. 
33. Wells, D.J., Wells, K.E., Asante, E.A., Turner, G., Sunada, Y., Campbell, K.P., 
Walsh, F.S. and Dickson, G. Expression of human full-length and minidystrophin in 
transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. 
Hum. Mol. Genet. 4 (1995) 1245-1250. 
34. Matsumura, K., Tome, F.M., Collin, H., Leturcq, F., Jeanpierre, M., Kaplan, J.C., 
Fardeau, M. and Campbell, K.P. Expression of dystrophin-associated proteins in 
dystrophin-positive muscle fibers (revertants) in Duchenne muscular dystrophy. 
Neuromuscul. Disord. 4 (1994) 115-120. 
35. Rafael, J.A., Sunada, Y., Cole, N.M., Campbell, K.P., Faulkner, J.A. and 
Chamberlain, J.S. Prevention of dystrophic pathology in mdx mice by a truncated 
dystrophin isoform. Hum. Mol. Genet. 3 (1994) 1725-1733. 
36. Mizuno, Y., Yoshida, M., Nonaka, I., Hirai, S. and Ozawa, E. Expression of utrophin 
(dystrophin-related protein) and dystrophin-associated glycoproteins in muscles from 
patients with Duchenne muscular dystrophy. Muscle Nerve 17 (1994) 206-216. 
37. Crawford, G.E., Faulkner, J.A., Crosbie, R.H., Campbell, K.P., Froehner, S.C. and 
Chaberlain, J.S. Assembly of the Dystrophin- associated Protein Complex Does Not 
Require the Dystrophin COOH-terminal Domain. J. Cell Biol. 150 (2000) 1399-1409. 
38. DelloRusso, C., Scott, J., Hartigan-O'Connor, D., Salvatori, G., Barjot, C., Robinson, 
A., Crawford, R., Brooks, S. and Chamberlain, J.S. Functional correction of adult mdx 
mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. 
Natl. Acad. Sci. USA 99 (2002) 12979-12984. 
39. Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps, S.F., 
Harper, H.A., Robinson, A.S., Engelhardt, J.F., Brooks, S.V. and Chamberlain, J.S. 
Modular flexibility of dystrophin: implications for gene therapy of Duchenne 
muscular dystrophy. Nature Med. 8 (2002) 253-261. 
40. Gardner, K., Kearney, J., Edwards, J. and Rafael-Fortney, J. Restoration of all 
dystrophin protein interactions by functional domains in trans does not rescue 
dystrophy. Gene therapy 13 (2005) 744-751. 
41. Ervasti, J. and Campbell, K. A Role for the Dystrophin-Glycoprotein Complex as a 
Transmembrane Linker between Laminin and Actin. J. Cell Biol. 122 (1993) 809-823. 
42. Rouger, K., Brault, M., Daval, N., Leroux, I., Guigand, L., Lesoeur, J. and Chérel, Y. 
Muscle satellite cell heterogeneity: in vitro and in vivo evidences for populations that 
fuse differently. Cell Tissue Res. 317 (2004) 319-326. 
43. Yamada, H., Saito, F., Fukuta-Ohi, H., Zhong, D., Hase, A., Arai, K., Okuyama, A., 
Maekawa, R., Shimizu, T. and Matsumura K. Processing of -dystroglycan by matrix 
metalloproteinase disrupts the link between the extracellular matrix and cell 
membrane via the dystroglycan complex. Hum. Mol. Genet. 10 (2001) 1563-1569. 
  16 
44. Armstrong, S., Latham, C. and Ganote, C. An ischemic beta-dystroglycan degradation 
product: correlation with irreversible injury in adult rabbit cardiomyocytes. Mol. Cell. 
Biochem. 242 (2003) 71-79. 
45. Bierczynska-Krzysik, A., Kang, S.U., Silberrring, J. and Lubec, G. Mass 
spectrometrical identification of brain proteins including highly insoluble and 
transmembrane proteins. Neurochem. Int. 49 (2006) 245-255. 
46. Zhou, J., Zhou, T., Cao, R., Liu, Z., Shen, J., Chen, P., Wang, X. and Liang, S. 
Evaluation of the application of sodium deoxycholate to proteomic analysis of rat 
hippocampal plasma membrane. J. Proteome Res. 5 (2006) 2547-2553. 
47. Galvin, J.E., Palamand, D., Strider, J., Milone, M. and Pestronk, A. The muscle 
protein dysferlin accumulates in the Alzheimer brain. Acta Neuropathol. 112 (2006) 
665-671. 
48. Wong, S.L., Chan, W.M. and Chan, H. Y. Sodium dodecyl sulfate-insoluble oligomers 
are involved in polyglutamine degeneration. Faseb J. (2008)  
49. Cappai, R., Leck, S.L., Tew, D.J., Williamson, N.A., Smith, D.P., Galatis, D., 
Sharples, R.A., Curtain, C.C., Ali, F.E., Cherny, R.A., Culvenor, J.G., Bottomley, 
S.P., Masters, C.L., Barnham, K.J. and Hill, A.F. Dopamine promotes alpha-synuclein 
aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. 
Faseb J. 19 (2005) 1377-1379. 
50. Greenberg, D.S., Sunada, Y., Campbell, K.P., Yaffe, D. and Nudel, U. Exogenous 
Dp71 restores the levels of dystrophin-associated proteins but does not alleviate 
muscle damage in mdx mice. Nature Genet. 8 (1994) 340-344. 
51. Rezniczek, G.A., Konieczny, P., Nikolic, B., Reipert, S., Schneller, D., 
Abrahamsberg, C., Davies, K.E., Winder, S.J. and Wiche, G. Plectin 1f scaffolding at 
the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with 
beta-dystroglycan. J. Cell Biol. 176 (2007) 965-977. 
52. Batchelor, C.L. and Winder, S.J. Sparks, signals and shock absorbers: how dystrophin 
loss causes muscular dystrophy. Trends Cell Biol. 16 (2006) 198-205. 
53. Hack, A., Groth, M. and McNally, E.M. Sarcoglycans in muscular dystrophy. 
Microsc. Res. Tech. 48 (2000) 167-180. 
 
